SLXN · Silexion Therapeutics Corp · Financials
Substantial doubt about the company's ability to continue as a going concern.
“our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and six-month periods ended June 30, 2026 included in this quarterly report, but rather, under our current business plan, through the fourth quarter of 2026 and, as a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $155K | $155K | $28K | $153K | |
| $9.11M | $7.14M | $5.82M | $3.71M | |
| $5.01M | $4.49M | $6.76M | $973K | |
| $14.13M | $11.63M | $12.57M | $4.68M | |
| -$14.13M | -$11.63M | -$12.57M | -$4.68M | |
| $2000 | $13K | $27K | $0 | |
| -$169K | $277K | $3.94M | $395K | |
| -$13.96M | -$11.91M | -$16.51M | -$5.08M | |
| — | $3000 | $10K | $32K | |
| -$13.96M | -$11.91M | -$16.52M | -$5.11M | |
| — | $0 | $76K | $166K | |
| — | $11.91M | $16.44M | $4.94M | |
| USD/shares | $21.68 | $89.60 | $3,949.40 | $6,634.50 |
| USD/shares | $21.68 | $89.60 | $3,949.40 | $6,634.50 |
| shares | — | 132.95K | 4163.5 | 744.84 |
| shares | — | 132.95K | 4163.5 | 744.84 |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 199,000 | 10-Q filed 2026-08-14 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 226,000 | 10-Q filed 2026-08-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 105 similar-size Biotechnology companies (of 532 listed).